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Abstract 
Background 
We performed a retrospective analysis to evaluate the efficacy of VA-ECMO 
support in cardiogenic shock based on various etiologies. 
Methods 
We retrospectively analyzed 99 patients supported with VA-ECMO from January 1, 
2012 to January 1, 2015. Outcomes included survival to discontinuation of VA-
ECMO support and survival to hospital discharge. The etiologies of cardiogenic 
shock included cardiac arrest (CPR), acute myocardial infarction (AMI), 
decompensated congestive heart failure (CHF), pulmonary embolism (PE), right 
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ventricular failure (RVF) not secondary to an acute pulmonary embolism, and post-
cardiotomy syndrome (PCS). The PCS group was used as a reference group; 
odds ratios were estimated and Fisher’s exact tests were performed to compare 
each other group to the reference. 
Results 
Patients supported with VA-ECMO due to PE and CHF had better survival to 
hospital discharge (83.3% and 54.2%, with p = 0.003 and p = 0.011, respectively) 
versus the PCS group (7.7%). The PE, CHF, and AMI groups had statistically 
improved survival to VA-ECMO discontinuation. There was no statistically 
significant difference in survival to VA-ECMO discontinuation or hospital discharge 
in four subgroup analyses. 
Conclusions 
Patients supported with VA-ECMO in cardiogenic shock due to PE or CHF 
demonstrated increased rates of survival to hospital discharge when compared to 
the PCS group. This study also highlights the need for a more uniform system of 
categorizing etiologies of cardiogenic shock. 
Keywords:  Venoarterial extracorporeal membrane oxygenation, refractory 
cardiogenic shock, heart failure, pulmonary embolism, mechanical circulatory 
support 
 
 
Introduction 
 
Extracorporeal membrane oxygenation (ECMO), also known as extracorporeal life 
support (ECLS), has been available as a life-saving means of supporting 
respiratory or cardiac function since the 1970’s.1,2 The first successful use of 
venoarterial ECMO (VA-ECMO) was reported in 1972.3 The first successful use of 
ECMO for treatment of cardiogenic shock was in 1973.4 However, during this era 
there was no proven survival advantage over conventional management, largely 
due to high complication rates.1,2 There has been a renewed interest in the use of 
ECMO for cardiopulmonary disease5,6, mostly due to technological advances, 
improved risk-benefit profile6-9, and increasing evidence and experience.5,6  
ECMO is an invasive technique that allows for the oxygenation of deoxygenated 
blood. Deoxygenated blood is drained from the venous system, pumped through 
an oxygenator, and then re-infused to the patient. This allows for the exchange of 
carbon dioxide and oxygen. Veno-venous ECMO (VV-ECMO) can be used to 
bypass the lung and oxygenate blood when only respiratory support is 
necessary.10 VA-ECMO bypasses both the heart and lungs, and thus can be 
utilized to provide both circulatory and respiratory support to patients with 
significantly impaired cardiac function, with or without impaired gas exchange.11 
The primary goal of this analysis was to evaluate the efficacy of VA-ECMO support 
for cardiogenic shock based on the underlying etiology, and to identify patient 
populations that derive the most benefit from VA-ECMO support. Outcomes 
evaluated included survival to VA-ECMO decannulation and survival to hospital 
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discharge. In addition, we evaluated these outcomes in the following subgroups: 
cardiogenic shock due to primarily right ventricular failure vs. primarily left 
ventricular failure, peripheral vs. central VA-ECMO access site, VA-ECMO 
cannulation performed by cardiothoracic surgery (CTS) vs. interventional 
cardiology, and post-cannulation management by either the cardiology critical care 
service vs. other critical care services.  
Methods 
Following institutional review board approval, data were collected by a combination 
of chart review of our institution’s electronic medical record and data collected by 
the members of the mechanical circulatory support (MCS) team. Cases in which 
only VV-ECMO was used were excluded. For individual patients who were 
cannulated multiple times during one admission, each cannulation was counted as 
one initiation of VA-ECMO. Data regarding date of death were obtained via our 
institution’s inpatient and outpatient medical records, as well as an internet search 
of the Social Security Death Index and obituaries.  
All patients were thought to be in cardiogenic shock as a primary indication for VA-
ECMO initiation. Distinguishing the etiology of cardiogenic shock proved difficult 
because it was very common for patients to have multiple pathologic processes 
contributing to shock. We defined the following groups for etiologies of cardiogenic 
shock: cardiac arrest and subsequent cardiopulmonary resuscitation (CPR), acute 
myocardial infarction (AMI), decompensated congestive heart failure (CHF), acute 
pulmonary embolism (PE), right ventricular failure (RVF) not secondary to an acute 
pulmonary embolism, and post-cardiotomy syndrome (PCS).   
The patients in the CPR group were found to be in cardiogenic shock post cardiac 
arrest or with ongoing CPR. The cardiac arrest event for each patient was 
secondary to a variety of primary etiologies, including but not limited to AMI, PE, 
hypoxic respiratory failure, RVF, primary arrhythmia, and PCS. The patients in the 
AMI group were thought to have had an acute coronary thrombosis resulting in 
either a ST segment elevation myocardial infarction (STEMI) or non-ST segment 
elevation myocardial infarction (NSTEMI) with subsequent cardiogenic shock. The 
patients in the CHF group had varying etiologies of decompensated heart failure. 
The majority of this group had known severe, acute on chronic CHF. This group 
also included less frequent etiologies of acute decompensated heart failure such 
as peripartum cardiomyopathy, acute myocarditis, and stress-induced 
cardiomyopathy secondary to a pheochromocytoma. The patients in the PCS 
group underwent CTS for a variety of reasons. The majority of these patients 
developed cardiogenic shock following coronary artery bypass grafting (CABG) or 
valvular surgery, and failed weaning from cardiopulmonary bypass in the operating 
room. Some of these patients had undergone cardiac surgery for less frequent 
reasons such as carcinoid syndrome with valvular involvement or orthotropic heart 
transplant. The PE group included patients that were in cardiogenic shock 
secondary to acute, massive PE. The RVF group included patients with pulmonary 
conditions ranging from primary arterial pulmonary hypertension to pulmonary 
hypertension secondary to interstitial lung disease, but did not include patients with 
acute PE.   
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For survival to decannulation, each episode of VA-ECMO cannulation was used, 
resulting in 106 events for analysis. For survival to hospital discharge the number 
of individual patients was used, resulting in 99 events. Because some individual 
patients were placed on VA-ECMO multiple times for different etiologies of 
cardiogenic shock, the sum total of individuals cannulated for each etiology of 
cardiogenic shock was 102 as opposed to 99.  
Historically, PCS was the most common indication for the utilization of VA-ECMO. 
The Nationwide Inpatient Sample database reports that the PCS group comprised 
80% of all ECMO utilizations, and that cardiogenic shock comprised 16% in 1998. 
In 2009, 40% of ECMO initiations were due to PCS and 39% were due to 
cardiogenic shock.12 Comprising the PCS group of all patients who failed weaning 
from cardiopulmonary bypass in the perioperative setting is consistent with other 
similar retrospective analyses.11,13,14 Because PCS is historically the most common 
indication for VA-ECMO initiation, and this group had the lowest rate of survival to 
decannulation and hospital discharge, the PCS group (n = 13) was used as a 
reference group for calculating estimated odds ratios (OR) and accompanying 
95% confidence intervals (CI). This method has been used by Carrol et al. in a 
similar retrospective analyses.14 Fisher’s exact test was used to acquire p-values.    
When the necessary information was available in the electronic medical record, we 
further analyzed survival by separating occurrences of VA-ECMO into subgroups:  
cardiogenic shock due to primarily left ventricular failure vs. primarily right 
ventricular failure; peripheral vs. central access for VA-ECMO; VA-ECMO initiation 
performed by either CTS vs. an interventional cardiologist; and primary 
management post-cannulation by either the critical care cardiology service vs. 
other services.  
The six main groups were compared on age and gender using one-way analysis of 
variance and a version of Fisher’s exact test for larger contingency tables, 
respectively. 
A p-value less than 0.05 was regarded as statistically significant. Data analysis 
was performed using Excel 2013 and SAS Version 9.3. 
Results 
Between January 1, 2012, and January 1, 2015, VA-ECMO was initiated to 
provide support for cardiogenic shock in 99 patients on 106 occasions at our 
institution. Of these 99 individual patients, 67 (67.7%) were male and 32 (32.3%) 
were female.  The mean +SD age was 51.3 ±14.9 years. The groups with the 
lowest mean age were the CHF and RVF groups, with mean ages of 
approximately 49 years. The groups with the highest mean age were the AMI and 
PE groups, with mean ages of approximately 57 years. However, the variation in 
mean ages across groups was not significant (p = 0.527). All groups were in their 
majority male, with the exception of the PE group, which was evenly divided in 
gender. The variation in gender ratios across groups was not significant (p = 
0.597). The baseline characteristics are summarized in Table 1.  
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Table 1. Baseline characteristics: mean age and gender for each group. 
 Mean Age (SD) Male (%) Female (%) 
Total 51.3 (14.9) 67 (67.7%) 32 (32.3%) 
CPR 49.8 (15.1) 25 (78.1%) 7 (21.9%) 
AMI 57.4 (10.8) 8 (72.7%) 3 (27.3%) 
CHF 48.8 (15.9) 16 (66.7%) 8 (33.3%) 
PE 56.5 (13.8) 3 (50.0%) 3 (50.0%) 
RVF 48.5 (14.6) 9 (56.3%) 7 (43.8%) 
PCS 53.3 (18.0) 9 (69.2%) 4 (30.8%) 
 
Note: Some persons belonged to more than one group. Within each row, however, each 
person is counted only once.  
Results regarding rates of survival to ECMO discontinuation and survival to 
hospital discharge are furnished in Table 2 and Table 3, respectively.  
Table 2. Survival to decannulation, using post-cardiotomy syndrome as the 
reference group 
 Total # Cannulations Survived to Decannulation OR (survival) p-value OR (dying) 
 N % N % (95% CI)  (95% CI) 
Total 106 100.0% 55 51.9%    
CPR 32 30.2% 12 37.5% 2.00 (0.46-8.74) 0.492 0.50 (0.11-2.19) 
AMI 13 12.3% 9 69.2% 7.50 (1.31-43.0) 0.047 0.13 (0.02-0.76) 
CHF 26 24.5% 20 76.9% 11.1 (2.29-54.0) 0.002 0.09 (0.02-0.44) 
PE 6 5.7% 5 83.3% 16.7 (1.36-204.0) 0.041 0.06 (0.05-0.73) 
RVF 16 15.1% 6 37.5% 2.00 (0.39-10.3) 0.454 0.50 (0.10-2.58) 
PCS 13 12.3% 3 23.1% 1.00 (reference)  1.00 (reference) 
 
Note: OR = estimated odds ratio, CI = confidence interval. 
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Table 3. Survival to hospital discharge, using post-cardiotomy syndrome as 
the reference group 
 # Individuals Cannulated Survived to Discharge OR (survival) p-value OR (dying) 
 N % N % (95% CI)  (95% CI) 
Total 99 100.0% 36 36.4%    
CPR 32 32.3% 9 28.1% 4.70 (0.53-41.6) 0.238 0.21 (0.02-1.89) 
AMI 11 11.1% 5 45.5% 10.0 (0.94-105.9) 0.061 0.10 (0.01-1.06) 
CHF 24 24.2% 13 54.2% 14.18 (1.58-127.0) 0.011 0.07 (0.01-0.63) 
PE 6 6.1% 5 83.3% 60.0 (3.10-1160) 0.003 0.02 (0.001-0.32) 
RVF 16 16.2% 4 25.0% 4.00 (0.39-41.2) 0.343 0.25 (0.02-2.58) 
PCS 13 13.1% 1 7.7% 1.00 (reference)  1.00 (reference) 
Note: Some persons belonged to more than one group. Within each row, however, each 
person is counted only once. OR = estimated odds ratio, CI = confidence interval.  
 
For the 106 occurrences of VA-ECMO initiation, survival to weaning of VA-ECMO 
support occurred on 55 (51.9%) occasions. Survival to hospital discharge occurred 
for 36 of the 99 (36.4%) individual patients.  
For the PCS group (the reference group) survival to ECMO decannulation 
occurred in three of the 13 events (23.1%) of ECMO initiation. Only one of the 13 
(7.7%) patients initiated on VA-ECMO survived to hospital discharge.  
The AMI, CHF, and PE groups had significantly higher rates of survival to ECMO 
decannulation than the reference group. For the 13 initiations of VA-ECMO in the 
AMI group, nine (69.2%) survived to ECMO decannulation (p = 0.047). For the 26 
initiations in the CHF group, 20 (76.9%) survived (p = 0.002). For the six initiations 
in the PE group, five (83.3%) survived (p = 0.041).  
The CHF and PE groups had significantly higher rates of survival to hospital 
discharge than the reference group. For the CHF group, 13 of the 24 (54.2%) 
individuals supported with VA-ECMO survived to hospital discharge (p = 0.011). 
For the PE group, five of six (83.3%) individuals survived (p = 0.003). Of note, all 
patients in the PE group who survived to ECMO decannulation survived to hospital 
discharge.  
Additional analyses were performed to evaluate other factors in relation to survival 
to VA-ECMO decannulation and survival to hospital discharge. These factors 
included whether the patient was in cardiogenic shock due to primarily left 
ventricular failure vs. primarily right ventricular failure, central vs. peripheral VA-
ECMO access, VA-ECMO cannulation performed by CTS vs. interventional 
cardiology, and post-cannulation management by the cardiovascular critical care 
team vs. a different inpatient service.  There was no significant difference in 
survival to ECMO discontinuation or survival to hospital discharge between any of 
these groups.  The results appear in Table 4 and Table 5.  
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Table 4. Subgroup analysis of survival to VA-ECMO discontinuation 
 Total # Cannulations 
Survived to Decannulation  
(n, %) 
OR Survival 
(95%, CI) 
p-value OR Death (95%, CI) 
LV Failure 70 37 52.9% 1.35 (0.59-3.09) 0.531 0.74 (0.32-1.71) 
RV Failure 33 15 45.5% 1.00 (reference)  1.00 (reference) 
Peripheral 74 36 48.6% 0.63 (0.27-1.49) 0.387 1.58 (0.67-3.75) 
Central 30 18 60.0% 1.00 (reference)  1.00 (reference) 
CTS 91 44 48.4% 0.47 (0.15-1.48) 0.266 2.14 (0.68-6.74) 
Interventional 
Cardiology 
15 10 66.7% 1.00 (reference)  1.00 (reference) 
CCU 41 20 48.8% 0.92 (0.42-2.02) 1.000 1.08 (0.5-2.37) 
Other 65 33 50.8% 1.00 (reference)  1.00 (reference) 
Note: OR = estimated odds ratio, CI = confidence interval.  
 
Table 5. Subgroup analysis of survival to hospital discharge 
 
Note: Some persons belonged to more than one group. Within each row, however, each 
person is counted only once. OR = estimated odds ratio, CI = confidence interval. 
 
 
 
 # Individuals Cannulated 
Survived to Discharge 
(n, %) 
OR Survival  
(95%, CI) 
p-
value 
OR Death (95%, 
CI) 
LV Failure 66 22 33.3% 0.73 (0.31-1.75) 0.507 1.37 (0.57-3.27) 
RV Failure 32 13 40.6% 1.00 (reference)  1.00 (reference) 
Peripheral 71 25 35.2% 0.72 (0.30-1.77) 0.497 1.38 (0.57-3.37) 
Central 28 12 42.9% 1.00 (reference)  1.00 (reference) 
CTS 85 28 32.9% 0.43 (0.14-1.31) 0.152 2.33 (0.77-7.06) 
Interventional 
Cardiology 15 8 53.3% 1.00 (reference)  1.00 (reference) 
CCU 39 14 35.9% 0.95 (0.41-2.18) 1.000 1.05 (0.46-2.42) 
Other 62 23 37.1% 1.00 (reference)  1.00 (reference) 
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Discussion 
In a retrospective analysis of patients with cardiogenic shock placed on VA-ECMO 
we found that there were 106 events in 99 individual patients, 36.4% of which 
survived to hospital discharge.  
Survival to VA-ECMO decannulation was better in the AMI, CHF, and PE groups 
when compared to the PCS group. Also, more patients with CHF and PE survived 
to discharge. 
There were no statistically significant survival differences in patients in cardiogenic 
shock due to primarily left ventricular failure vs. right ventricular failure, central 
ECMO cannulation vs. peripheral ECMO cannulation, ECMO cannulation 
performed by CTS vs. interventional cardiology, or post-cannulation management 
by the cardiology critical care service vs. other inpatient services.   
This retrospective analysis was performed to identify patient populations that may 
derive greater benefit from VA-ECMO as a means of providing MCS for patients in 
cardiogenic shock. We grouped patients supported by VA-ECMO by the 
underlying etiology of cardiogenic shock to compare rates of survival to VA-ECMO 
discontinuation and survival to hospital discharge.  
Data demonstrating the efficacy of VA-ECMO support in the setting of cardiogenic 
shock largely comes from retrospective analyses such as this.14-17 There is 
considerable variability in the documentation of the etiologies of cardiogenic shock 
in the VA-ECMO literature.15 For example, in the Extracorporeal Life Support 
Organization (ELSO) ECLS Registry Report from January 2015, patients placed 
on ECLS for cardiac causes were grouped into the following categories: congenital 
defect, cardiac arrest, cardiogenic shock, cardiomyopathy, myocarditis, and other. 
In this system, more patients were included in the “other” group (1,785) than all 
other groups combined (1,621).18 Because of this variability, it is difficult to 
evaluate the efficacy of VA-ECMO in the setting of cardiogenic shock across 
different institutions. To better evaluate the efficacy of VA-ECMO in cardiogenic 
shock due to specific pathological processes, a more uniform system to categorize 
patients in cardiogenic shock is necessary.  
Our grouping system consisting of CPR, AMI, CHF, RVF, PE, and PCS is efficient 
and intuitive, both separating clinically different etiologies of cardiogenic shock and 
representing the vast majority of patients in cardiogenic shock. The benefit of such 
a system is that these specific etiologies of cardiogenic shock differ in their 
pathophysiology, management, and prognosis. Carroll et al. used a similar system 
with the following etiologies: AMI, PE, acute cardiomyopathy, chronic 
cardiomyopathy, post-cardiotomy shock, or other. In this system, patients that 
suffered cardiac arrest were placed into a group based on the underlying 
pathologic process causing cardiac arrest, and placed in the “other” group if no 
underlying process was identified.14   
Patients who undergo CPR create difficulty with regard to classification. The ECLS 
registry defines extracorporeal membrane oxygenation for adults in cardiac arrest 
(eCPR) as the following: “extracorporeal life support (ECLS) used as part of initial 
resuscitation from cardiac arrest. Patients who are hemodynamically unstable and 
placed on ECLS without cardiac arrest are not considered E-CPR”.18  
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These patients typically undergo CPR due to a variety of underlying pathologic 
processes, such as AMI and PE. However, the fact that they suffer from cardiac 
arrest generally worsens their prognosis. In addition, these patients may not be in 
cardiogenic shock until they undergo cardiac arrest. Therefore, we assigned them 
their own group in our classification system. However, an argument can be made 
that these patients should be grouped based on the etiology of cardiac arrest. 
Also, there may be benefit in further dividing patients in the CHF group into 
patients with acute on chronic CHF and patients with acute decompensated CHF 
with no history of cardiomyopathy. Examples of patients that would fit in the latter 
division include those suffering from fulminant myocarditis or peripartum 
cardiomyopathy. Acutely decompensated CHF patients with no history of 
cardiomyopathy may be more likely to have a better prognosis due to potential 
reversibility, which may result in increased benefit to temporary support with VA-
ECMO.  
This analysis has limitations. It is retrospective as opposed to a prospective 
randomized controlled trial. However, the decision to initiate VA-ECMO support in 
these cases occurred in emergent situations, and in general VA-ECMO is initiated 
because patients are deemed to be at great risk of not surviving without it. The 
emergent nature of VA-ECMO initiation makes it difficult to propose a prospective 
randomized controlled trial, necessitating retrospective analyses which would 
benefit from a more uniform system of documentation across institutions.  
Another limitation is the relatively small number of patients in some of the 
cardiogenic shock etiology groups, even though the total of 99 patients supported 
with VA-ECMO over a three-year period is a substantial number for a single 
institution. The fact that survival to VA-ECMO decannulation and hospital 
discharge in the PE group was found to be significantly better than in the reference 
group, notwithstanding the small sample size in the PE group, highlights the 
effectiveness of VA-ECMO in this setting. In addition, the relatively small numbers 
of patients in some groups demonstrates the need for increased uniformity across 
institutions, so that data may be pooled for meta-analysis. 
Even with its limitations, this analysis provides valuable data regarding patients 
supported with VA-ECMO in cardiogenic shock. In particular, it demonstrates 
significantly increased rates of survival to hospital discharge in the CHF and PE 
groups versus PCS patients. In addition, we have proposed a classification system 
that can be used across institutions, so that larger numbers of patients can be 
pooled for meta-analysis to gain a better understanding of the efficacy of VA-
ECMO use for specific etiologies of cardiogenic shock. 
Conclusions 
In patients with cardiogenic shock and supported with VA-ECMO, the PCS group 
had the worst prognosis, with only 7.7% surviving to discharge. Patients with CHF 
and PE have the best prognosis, with 54.2% and 83.3% surviving to discharge, 
respectively. Prognosis was especially favorable for PE, where everyone who 
survived to decannulation was discharged alive. Our analysis underscores the 
need for functional, intuitive, and uniform classification of indications for VA 
ECMO. 
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